- TheStreet.com•32 minutes ago
Stocks hold lower by midday Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.
- 24/7 Wall St.•5 hours ago
In a time when government wrangling about drug prices is more than commonplace, news of a biosimilar for the mega-blockbuster Humira being approved took the backseat to many other things.
- Zacks•7 hours ago
Amgen, Inc. (AMGN) today announced the approval of Amjevita (adalimumab-atto), a biosimilar version to AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||173.33 x 200|
|Ask||173.37 x 300|
|Day's Range||172.90 - 174.42|
|52wk Range||130.09 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.69|
|Avg Vol (3m)||2,864,382|
|Dividend & Yield||4.00 (2.29%)|